Vivaldis Vetmaro Maropitant Citrate 24mg (Per Tablet)

Maropitant Citrate Tablets Antiemetic For Dogs Maropitant Citrate Tablets (Cerenia generic) ss an FDA-approved antiemetic formulated specifically for dogs. Maropitant Citrate is indicated for the prevention of acute vomiting and the prevention of vomiting due to motion sickness in dogs. Maropitant Citrate acts by blocking vomiting signals to the brain to prevent vomiting. Scored tablets for easy dosing Safe and effective treatment for vomiting due to a variety of causes Dosage and Administration : Maropitant Citrate Tablets are recommended for use in dogs 8 weeks and older. For Prevention of Acute Vomiting

Administer Maropitant Citrate Tablets orally at a minimum dose of 2 mg/kg (0.9 mg/lb) body weight once daily for up to 5 consecutive days.

Maropitant Citrate Tablets may be used interchangeably with Maropitant Injectable Solution for once daily dosing for the prevention of acute vomiting. For Prevention of Vomiting Due to Motion Sickness

Administer Maropitant Citrate Tablets orally at a minimum dose of 8 mg/kg (3.6 mg/lb) body weight once daily for up to 2 consecutive days. Dogs should be fasted 1 hour prior to administration of Maropitant Citrate Tablets. Administer Maropitant Citrate Tablets 2 hours prior to travel.

In puppies younger than 11 weeks of age, histological evidence of bone marrow hypoplasia was seen at higher frequency and greater severity in puppies treated with Maropitant Citrate than in control puppies. In puppies 16 weeks and older, bone marrow hypoplasia was not seen.

Precautions:

The safe use of Maropitant Citrate Tablets has not been evaluated in dogs used for breeding, pregnant or lactating bitches, dogs with gastrointestinal obstruction, or dogs that have ingested toxins. Use with caution in dogs with hepatic dysfunction. Use with caution with other medications that are highly protein bound. The concomitant use of Maropitant Citrate with other protein bound drugs has not been studied in dogs. Commonly used protein bound drugs include NSAIDs, cardiac, anticonvulsant and behavioral medications. The influence of concomitant drugs that may inhibit metabolism of Maropitant Citrate has not been evaluated. Drug compatibility should be monitored in patients requiring adjunctive therapy.

Warnings:

Not for use in humans. Keep out of reach of children. In case of accidental ingestion, seek medical advice. Topical exposure may elicit localized allergic skin reactions in some individuals. Repeated or prolonged exposure may lead to skin sensitization. Wash hands with soap and water after administering drug. Maropitant Citrate is also an ocular irritant. In case of accidental eye exposure, flush with water for 15 minutes and seek medical attention.